Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dinutuximab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-11 of 11 for your search:
Start Over
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Any age
Sponsor: NCI
Protocol IDs: NCI-2011-01997, COG-ANBL0931, CDR0000662673, ANBL0931, U10CA098543, NCT01041638
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 8 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: DIV-NB-201, NCT01592045
Phase II Study of MOAB Ch14.18 with GM-CSF for Recurrent Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: POG-9347
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: Children
Sponsor: NCI
Protocol IDs: NCI-2012-03125, COG-ANBL1221, CDR0000745188, ANBL1221, U10CA180886, U10CA098543, NCT01767194
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01527, 0935, CDR0000063533, COG-A0935A, CCG-0935, CCG-0935A, NCT00005576
Phase Ia/Ib Study of Chimeric Monoclonal Anti-GD2 Antibody 14.18 in Patients with Metastatic Melanoma (Summary Last Modified 06/93)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: UAB-185, NCI-B89-0005, B89-0005
Phase I Study of Melanoma-Reactive Chimeric Anti-GD-2 Monoclonal Antibody 14.18 plus IL-2 for Refractory Metastatic Melanoma (Summary Last Modified 11/94)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: WCCC-CO-9097, NCI-B90-0014, B90-0014
Phase I Study of Chimeric MOAB 14.18 plus GM-CSF for Metastatic Melanoma (Summary Last Modified 05/95)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to physiologic 70
Sponsor:
Protocol IDs: MDA-DM-90102, NCI-B93-0009, B93-0009
Phase I Pilot Study of Chimeric MOAB 14.18 for Refractory Small Cell Lung Cancer (Summary Last Modified 03/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-93049A4, NCI-B93-0001, B93-0001
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 15 and under
Sponsor: NCI
Protocol IDs: NCI-2011-02975, CDR0000701215, CHP-1002, 9122, NCT01418495
Start Over